892 related articles for article (PubMed ID: 19419923)
1. New options for integrating antiangiogenic therapy and platinum-based first-line chemotherapy for advanced non-small-cell lung cancer.
Manegold C
Clin Lung Cancer; 2008; 9 Suppl 3():S100-8. PubMed ID: 19419923
[TBL] [Abstract][Full Text] [Related]
2. Targeting the VEGF pathway: antiangiogenic strategies in the treatment of non-small cell lung cancer.
Aita M; Fasola G; Defferrari C; Brianti A; Bello MG; Follador A; Sinaccio G; Pronzato P; Grossi F
Crit Rev Oncol Hematol; 2008 Dec; 68(3):183-96. PubMed ID: 18606548
[TBL] [Abstract][Full Text] [Related]
3. Angiogenesis inhibition in the treatment of lung cancer.
Vokes E; Herbst R; Sandler A
Clin Adv Hematol Oncol; 2006 Nov; 4(11 Suppl 23):1-10; quiz 11-2. PubMed ID: 17143257
[TBL] [Abstract][Full Text] [Related]
4. Bevacizumab in non small cell lung cancer.
Sandler A
Clin Cancer Res; 2007 Aug; 13(15 Pt 2):s4613-6. PubMed ID: 17671151
[TBL] [Abstract][Full Text] [Related]
5. Investigating the potential of bevacizumab in other indications: metastatic renal cell, non-small cell lung, pancreatic and breast cancer.
de Gramont A; Van Cutsem E
Oncology; 2005; 69 Suppl 3():46-56. PubMed ID: 16301835
[TBL] [Abstract][Full Text] [Related]
6. Bevacizumab for the treatment of advanced non-small-cell lung cancer.
Manegold C
Expert Rev Anticancer Ther; 2008 May; 8(5):689-99. PubMed ID: 18471042
[TBL] [Abstract][Full Text] [Related]
7. Optimizing the dose and schedule of anti-vascular endothelial growth factor antibodies in non-small-cell lung cancer.
Klamerus JF; Brahmer JR
Clin Lung Cancer; 2008 Mar; 9 Suppl 2():S51-6. PubMed ID: 21884999
[TBL] [Abstract][Full Text] [Related]
8. Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies.
Shih T; Lindley C
Clin Ther; 2006 Nov; 28(11):1779-802. PubMed ID: 17212999
[TBL] [Abstract][Full Text] [Related]
9. Role of bevacizumab for the treatment of non-small-cell lung cancer.
Ramalingam S; Belani CP
Future Oncol; 2007 Apr; 3(2):131-9. PubMed ID: 17381412
[TBL] [Abstract][Full Text] [Related]
10. The role of bevacizumab in the treatment of non-small cell lung cancer: current indications and future developments.
Gridelli C; Maione P; Rossi A; De Marinis F
Oncologist; 2007 Oct; 12(10):1183-93. PubMed ID: 17962612
[TBL] [Abstract][Full Text] [Related]
11. The potential of antiangiogenic therapy in non-small cell lung cancer.
Giaccone G
Clin Cancer Res; 2007 Apr; 13(7):1961-70. PubMed ID: 17404076
[TBL] [Abstract][Full Text] [Related]
12. An indirect comparison of the efficacy of bevacizumab plus carboplatin and paclitaxel versus pemetrexed with cisplatin in patients with advanced or recurrent non-squamous adenocarcinoma non-small cell lung cancer.
Nuijten MJ; Aultman R; Carpeño Jde C; Vergnenègre A; Chouaid C; Walzer S; Siebert U
Curr Med Res Opin; 2011 Nov; 27(11):2193-201. PubMed ID: 21970659
[TBL] [Abstract][Full Text] [Related]
13. The emerging role of vascular endothelial growth factor receptor tyrosine kinase inhibitors.
Langer CJ; Natale RB
Semin Oncol; 2005 Dec; 32(6 Suppl 10):S23-9. PubMed ID: 16459176
[TBL] [Abstract][Full Text] [Related]
14. Bevacizumab plus platinum-based chemotherapy: in advanced non-small cell lung cancer.
Wagstaff AJ; Keam SJ; McCormack PL
BioDrugs; 2009; 23(3):187-96. PubMed ID: 19627170
[TBL] [Abstract][Full Text] [Related]
15. Emerging safety data for bevacizumab in advanced non-small-cell lung cancer.
Hirsh V
Clin Lung Cancer; 2008 Mar; 9 Suppl 2():S62-70. PubMed ID: 21885001
[TBL] [Abstract][Full Text] [Related]
16. Combination of paclitaxel and bevacizumab in heavily pre-treated non-small-cell lung cancer (NSCLC) patients: a case series study on 15 patients.
Le Moulec S; Hadoux J; Gontier E; Chargari C; Helissey C; Lamand V; Tanz R; Farace F; Vedrine L; Bonardel G; Soria JC; Besse B
Bull Cancer; 2013 Dec; 100(12):30-7. PubMed ID: 24316967
[TBL] [Abstract][Full Text] [Related]
17. Anti-vascular endothelial growth factor monoclonals in non-small cell lung cancer.
Sandler AB; Johnson DH; Herbst RS
Clin Cancer Res; 2004 Jun; 10(12 Pt 2):4258s-4262s. PubMed ID: 15217970
[TBL] [Abstract][Full Text] [Related]
18. Bevacizumab in non-small-cell lung cancer: a review.
Planchard D
Expert Rev Anticancer Ther; 2011 Aug; 11(8):1163-79. PubMed ID: 21916570
[TBL] [Abstract][Full Text] [Related]
19. First-line treatment for advanced non-small-cell lung cancer.
Laskin JJ; Sandler AB
Oncology (Williston Park); 2005 Nov; 19(13):1671-6; discussion 1678-80. PubMed ID: 16425521
[TBL] [Abstract][Full Text] [Related]
20. Bevacizumab in non-small cell lung cancer.
Di Costanzo F; Mazzoni F; Micol Mela M; Antonuzzo L; Checcacci D; Saggese M; Di Costanzo F
Drugs; 2008; 68(6):737-46. PubMed ID: 18416583
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]